British researchers claim that marijuana may have appetite suppressant qualities, and could possibly be used to treat obesity. GW Pharmaceuticals (same people that invented Sativex) has announced that they have made new discoveries involving cannabidiol and THCV. According to E-Max Health, “researchers have discovered compounds in marijuana that could help in the management of metabolic diseases such as type 2 diabetes.”
Dr. Steph Wright, director of research and development at GW Pharmaceuticals, said “four Phase 2 clinical trials will have results by the end of the year that might help develop a drug used to treat patients suffering from ‘metabolic syndrome’ — a risk factor for heart disease,” according to Upi.com.
Mike Cawthorne, director of metabolic research at the University of Buckingham who has been conducting the animal studies, told Health India: “Over all, it seems these molecules increase energy expenditure in the cells of the body by increasing the metabolism.”
This is an outstanding day for cannabis science and those suffering from type 2 diabetes. Everything is preliminary at this point, but anything that can lead to relief for the enormous population of those diagnosed with type 2 diabetes is a great thing. Below are some amazing videos if you would like to become more familiar with cannabidiol and THCV: